Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | Varied outcomes in patients with AML harboring poor-risk cytogenetics with or without TP53 mutation

Daniel Pollyea • 7 Sep 2023
SOHO 2023
Acute Myeloid Leukemia Leukemia Venetoclax

Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, briefly discusses the outcomes of patients with acute myeloid leukemia (AML) harboring poor-risk cytogenetics and TP53 mutation treated with venetoclax-based regimens. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Daniel Pollyea

1:08
The importance of predicting venetoclax response in patients with AML
Daniel Pollyea • 7 Sep 2023
1:00
The potential use of multi-gene molecular MRD testing in AML
Daniel Pollyea • 7 Sep 2023
1:13
Addressing whether AML with monocytic features should be considered a distinct clinical entity
Daniel Pollyea • 7 Sep 2023
1:43
Targeting MDS stem cells with omacetaxine and azacitidine
Daniel Pollyea • 10 Dec 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals